Characterization of the Topoisomerase I Locus in Human Colorectal Cancer
DNA topoisomerase I (topo I) is the principle target for Camptothecin and its analogues. The topo I gene is located on chromosome 20q11.2–q13.1 and variation in topo I gene copy number has been shown to have impact on the in vitro sensitivity to topoisomerase I inhibitor chemotherapy. Fluorescence i...
Gespeichert in:
Veröffentlicht in: | Cancer genetics and cytogenetics 2000-08, Vol.121 (1), p.56-60 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 60 |
---|---|
container_issue | 1 |
container_start_page | 56 |
container_title | Cancer genetics and cytogenetics |
container_volume | 121 |
creator | Boonsong, Attasit Marsh, Sharon Rooney, Patrick H Stevenson, David A.J Cassidy, James McLeod, Howard L |
description | DNA topoisomerase I (topo I) is the principle target for Camptothecin and its analogues. The topo I gene is located on chromosome 20q11.2–q13.1 and variation in topo I gene copy number has been shown to have impact on the in vitro sensitivity to topoisomerase I inhibitor chemotherapy. Fluorescence in situ hybridization (FISH) was used to detect and compare the TOPO I gene copy number between metaphase and interphase nuclei in a panel of 7 colorectal cancer cell lines. TOPO I gene copy number varied from 2 to 8 between cell lines, and signal in interphase nuclei demonstrated a linear relationship with that detected in metaphase nuclei. The structure of gene amplification included isochromosome formation, amplicon extension, and marker chromosome generation. Comparative genomic hybridization (CGH) was then used to further define the region of gain on chromosome 20. The region of gain contained the topo I gene and involved nearly all of 20q in most cases. This demonstrates a high degree of intrinsic variation in topo I gene copy number and the involvement of a 20q amplicon in colorectal cancer, which may have important implications for colorectal tumorigenesis and the use of chemotherapy. |
doi_str_mv | 10.1016/S0165-4608(00)00242-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72210359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165460800002429</els_id><sourcerecordid>72210359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-f91852dbaaafcce788ac3bc0d8cd33d56e677af0520a4eb320f99ec383ea21eb3</originalsourceid><addsrcrecordid>eNqFkE1P3DAQQK0KVJYtP6HIB1TRQ-jYjpP4hKqo7SKtxAE4W7PORBgl8WInldpf3yy7Kty4zEijN1-Psc8CrgSI4tvdHHSWF1BdAnwFkLnMzAe2EFWpsjzXxRFb_EdO2GlKTwBQSlN8ZCcCjK5MLhdsVT9iRDdS9H9x9GHgoeXjI_H7sA0-hZ4iJuI3fB3clLgf-GrqceB16EIkN2LHaxwcxU_suMUu0dkhL9nDzx_39Spb3_66qb-vM6cMjFlrRKVls0HE1jkqqwqd2jhoKtco1eiCirLEFrQEzGmjJLTGkFOVIpRiLizZl_3cbQzPE6XR9j456jocKEzJllIKUNrMoN6DLoaUIrV2G32P8Y8VYHcK7YtCu_NjAeyLQrvrOz8smDY9NW-69s5m4OIAYHLYtXH-36dXTkOhQczY9R6j2cZvT9Em52lW1fidONsE_84l_wA3b42k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72210359</pqid></control><display><type>article</type><title>Characterization of the Topoisomerase I Locus in Human Colorectal Cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Boonsong, Attasit ; Marsh, Sharon ; Rooney, Patrick H ; Stevenson, David A.J ; Cassidy, James ; McLeod, Howard L</creator><creatorcontrib>Boonsong, Attasit ; Marsh, Sharon ; Rooney, Patrick H ; Stevenson, David A.J ; Cassidy, James ; McLeod, Howard L</creatorcontrib><description>DNA topoisomerase I (topo I) is the principle target for Camptothecin and its analogues. The topo I gene is located on chromosome 20q11.2–q13.1 and variation in topo I gene copy number has been shown to have impact on the in vitro sensitivity to topoisomerase I inhibitor chemotherapy. Fluorescence in situ hybridization (FISH) was used to detect and compare the TOPO I gene copy number between metaphase and interphase nuclei in a panel of 7 colorectal cancer cell lines. TOPO I gene copy number varied from 2 to 8 between cell lines, and signal in interphase nuclei demonstrated a linear relationship with that detected in metaphase nuclei. The structure of gene amplification included isochromosome formation, amplicon extension, and marker chromosome generation. Comparative genomic hybridization (CGH) was then used to further define the region of gain on chromosome 20. The region of gain contained the topo I gene and involved nearly all of 20q in most cases. This demonstrates a high degree of intrinsic variation in topo I gene copy number and the involvement of a 20q amplicon in colorectal cancer, which may have important implications for colorectal tumorigenesis and the use of chemotherapy.</description><identifier>ISSN: 0165-4608</identifier><identifier>EISSN: 1873-4456</identifier><identifier>DOI: 10.1016/S0165-4608(00)00242-9</identifier><identifier>PMID: 10958942</identifier><identifier>CODEN: CGCYDF</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Biological and medical sciences ; Caco-2 Cells ; Chromosome Aberrations ; Chromosomes, Human, Pair 20 - genetics ; Colorectal Neoplasms - enzymology ; Colorectal Neoplasms - genetics ; DNA Topoisomerases, Type I - genetics ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Dosage ; HT29 Cells ; Humans ; In Situ Hybridization, Fluorescence ; Interphase ; Medical sciences ; Metaphase ; Nucleic Acid Hybridization ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>Cancer genetics and cytogenetics, 2000-08, Vol.121 (1), p.56-60</ispartof><rights>2000 Elsevier Science Inc.</rights><rights>2000 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-f91852dbaaafcce788ac3bc0d8cd33d56e677af0520a4eb320f99ec383ea21eb3</citedby><cites>FETCH-LOGICAL-c390t-f91852dbaaafcce788ac3bc0d8cd33d56e677af0520a4eb320f99ec383ea21eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165460800002429$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1506501$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10958942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boonsong, Attasit</creatorcontrib><creatorcontrib>Marsh, Sharon</creatorcontrib><creatorcontrib>Rooney, Patrick H</creatorcontrib><creatorcontrib>Stevenson, David A.J</creatorcontrib><creatorcontrib>Cassidy, James</creatorcontrib><creatorcontrib>McLeod, Howard L</creatorcontrib><title>Characterization of the Topoisomerase I Locus in Human Colorectal Cancer</title><title>Cancer genetics and cytogenetics</title><addtitle>Cancer Genet Cytogenet</addtitle><description>DNA topoisomerase I (topo I) is the principle target for Camptothecin and its analogues. The topo I gene is located on chromosome 20q11.2–q13.1 and variation in topo I gene copy number has been shown to have impact on the in vitro sensitivity to topoisomerase I inhibitor chemotherapy. Fluorescence in situ hybridization (FISH) was used to detect and compare the TOPO I gene copy number between metaphase and interphase nuclei in a panel of 7 colorectal cancer cell lines. TOPO I gene copy number varied from 2 to 8 between cell lines, and signal in interphase nuclei demonstrated a linear relationship with that detected in metaphase nuclei. The structure of gene amplification included isochromosome formation, amplicon extension, and marker chromosome generation. Comparative genomic hybridization (CGH) was then used to further define the region of gain on chromosome 20. The region of gain contained the topo I gene and involved nearly all of 20q in most cases. This demonstrates a high degree of intrinsic variation in topo I gene copy number and the involvement of a 20q amplicon in colorectal cancer, which may have important implications for colorectal tumorigenesis and the use of chemotherapy.</description><subject>Biological and medical sciences</subject><subject>Caco-2 Cells</subject><subject>Chromosome Aberrations</subject><subject>Chromosomes, Human, Pair 20 - genetics</subject><subject>Colorectal Neoplasms - enzymology</subject><subject>Colorectal Neoplasms - genetics</subject><subject>DNA Topoisomerases, Type I - genetics</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Dosage</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Interphase</subject><subject>Medical sciences</subject><subject>Metaphase</subject><subject>Nucleic Acid Hybridization</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0165-4608</issn><issn>1873-4456</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQQK0KVJYtP6HIB1TRQ-jYjpP4hKqo7SKtxAE4W7PORBgl8WInldpf3yy7Kty4zEijN1-Psc8CrgSI4tvdHHSWF1BdAnwFkLnMzAe2EFWpsjzXxRFb_EdO2GlKTwBQSlN8ZCcCjK5MLhdsVT9iRDdS9H9x9GHgoeXjI_H7sA0-hZ4iJuI3fB3clLgf-GrqceB16EIkN2LHaxwcxU_suMUu0dkhL9nDzx_39Spb3_66qb-vM6cMjFlrRKVls0HE1jkqqwqd2jhoKtco1eiCirLEFrQEzGmjJLTGkFOVIpRiLizZl_3cbQzPE6XR9j456jocKEzJllIKUNrMoN6DLoaUIrV2G32P8Y8VYHcK7YtCu_NjAeyLQrvrOz8smDY9NW-69s5m4OIAYHLYtXH-36dXTkOhQczY9R6j2cZvT9Em52lW1fidONsE_84l_wA3b42k</recordid><startdate>20000801</startdate><enddate>20000801</enddate><creator>Boonsong, Attasit</creator><creator>Marsh, Sharon</creator><creator>Rooney, Patrick H</creator><creator>Stevenson, David A.J</creator><creator>Cassidy, James</creator><creator>McLeod, Howard L</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000801</creationdate><title>Characterization of the Topoisomerase I Locus in Human Colorectal Cancer</title><author>Boonsong, Attasit ; Marsh, Sharon ; Rooney, Patrick H ; Stevenson, David A.J ; Cassidy, James ; McLeod, Howard L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-f91852dbaaafcce788ac3bc0d8cd33d56e677af0520a4eb320f99ec383ea21eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Biological and medical sciences</topic><topic>Caco-2 Cells</topic><topic>Chromosome Aberrations</topic><topic>Chromosomes, Human, Pair 20 - genetics</topic><topic>Colorectal Neoplasms - enzymology</topic><topic>Colorectal Neoplasms - genetics</topic><topic>DNA Topoisomerases, Type I - genetics</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Dosage</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Interphase</topic><topic>Medical sciences</topic><topic>Metaphase</topic><topic>Nucleic Acid Hybridization</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Boonsong, Attasit</creatorcontrib><creatorcontrib>Marsh, Sharon</creatorcontrib><creatorcontrib>Rooney, Patrick H</creatorcontrib><creatorcontrib>Stevenson, David A.J</creatorcontrib><creatorcontrib>Cassidy, James</creatorcontrib><creatorcontrib>McLeod, Howard L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer genetics and cytogenetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boonsong, Attasit</au><au>Marsh, Sharon</au><au>Rooney, Patrick H</au><au>Stevenson, David A.J</au><au>Cassidy, James</au><au>McLeod, Howard L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of the Topoisomerase I Locus in Human Colorectal Cancer</atitle><jtitle>Cancer genetics and cytogenetics</jtitle><addtitle>Cancer Genet Cytogenet</addtitle><date>2000-08-01</date><risdate>2000</risdate><volume>121</volume><issue>1</issue><spage>56</spage><epage>60</epage><pages>56-60</pages><issn>0165-4608</issn><eissn>1873-4456</eissn><coden>CGCYDF</coden><abstract>DNA topoisomerase I (topo I) is the principle target for Camptothecin and its analogues. The topo I gene is located on chromosome 20q11.2–q13.1 and variation in topo I gene copy number has been shown to have impact on the in vitro sensitivity to topoisomerase I inhibitor chemotherapy. Fluorescence in situ hybridization (FISH) was used to detect and compare the TOPO I gene copy number between metaphase and interphase nuclei in a panel of 7 colorectal cancer cell lines. TOPO I gene copy number varied from 2 to 8 between cell lines, and signal in interphase nuclei demonstrated a linear relationship with that detected in metaphase nuclei. The structure of gene amplification included isochromosome formation, amplicon extension, and marker chromosome generation. Comparative genomic hybridization (CGH) was then used to further define the region of gain on chromosome 20. The region of gain contained the topo I gene and involved nearly all of 20q in most cases. This demonstrates a high degree of intrinsic variation in topo I gene copy number and the involvement of a 20q amplicon in colorectal cancer, which may have important implications for colorectal tumorigenesis and the use of chemotherapy.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10958942</pmid><doi>10.1016/S0165-4608(00)00242-9</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-4608 |
ispartof | Cancer genetics and cytogenetics, 2000-08, Vol.121 (1), p.56-60 |
issn | 0165-4608 1873-4456 |
language | eng |
recordid | cdi_proquest_miscellaneous_72210359 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Biological and medical sciences Caco-2 Cells Chromosome Aberrations Chromosomes, Human, Pair 20 - genetics Colorectal Neoplasms - enzymology Colorectal Neoplasms - genetics DNA Topoisomerases, Type I - genetics Gastroenterology. Liver. Pancreas. Abdomen Gene Dosage HT29 Cells Humans In Situ Hybridization, Fluorescence Interphase Medical sciences Metaphase Nucleic Acid Hybridization Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
title | Characterization of the Topoisomerase I Locus in Human Colorectal Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T04%3A39%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20the%20Topoisomerase%20I%20Locus%20in%20Human%20Colorectal%20Cancer&rft.jtitle=Cancer%20genetics%20and%20cytogenetics&rft.au=Boonsong,%20Attasit&rft.date=2000-08-01&rft.volume=121&rft.issue=1&rft.spage=56&rft.epage=60&rft.pages=56-60&rft.issn=0165-4608&rft.eissn=1873-4456&rft.coden=CGCYDF&rft_id=info:doi/10.1016/S0165-4608(00)00242-9&rft_dat=%3Cproquest_cross%3E72210359%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72210359&rft_id=info:pmid/10958942&rft_els_id=S0165460800002429&rfr_iscdi=true |